- Previous Close
31.05 - Open
31.00 - Bid 31.00 x --
- Ask 31.10 x --
- Day's Range
30.75 - 31.10 - 52 Week Range
28.60 - 36.30 - Volume
132,208 - Avg. Volume
160,650 - Market Cap (intraday)
5.624B - Beta (5Y Monthly) 0.60
- PE Ratio (TTM)
18.48 - EPS (TTM)
1.68 - Earnings Date --
- Forward Dividend & Yield 1.00 (3.22%)
- Ex-Dividend Date Sep 4, 2024
- 1y Target Est
31.00
Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the production, processing, selling, and trading of various medicines, Chinese medicines, medical cosmetic products and nutrients in Taiwan, Mainland China, Vietnam, Indonesia, and internationally. It operates through three segments: Pharmaceuticals, Healthy Food, and Others. The company offers pharmaceutical products, including antineoplastic, ophthalmic, ENT, oral, respiratory system, dermatology, analgesic and NSAIDs, metabolic and nutrient, gastrointestinal, and other products; and healthy food under the Sinphar, DailyCare, Migus, YouBest, and SynCoreBio brands. It also provides moisturizer repair essence, anti aging cream, renewable oi, and UV defence cream under the DYNASKIN brand; serum, revitalizing cream, hygiene, sunblock, sunscreen, and lightening tables under the Yestuner brand; and shower gel and hair shampoo. In addition, the company is involved in the provision of testing and development, as well as product design and manufacturing services. The company was incorporated in 1977 and is based in Yilan City, Taiwan.
www.sinphar.com.twRecent News: 1734.TW
View MorePerformance Overview: 1734.TW
Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 1734.TW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 1734.TW
View MoreValuation Measures
Market Cap
5.62B
Enterprise Value
6.35B
Trailing P/E
18.48
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.79
Price/Book (mrq)
1.72
Enterprise Value/Revenue
2.02
Enterprise Value/EBITDA
10.56
Financial Highlights
Profitability and Income Statement
Profit Margin
9.67%
Return on Assets (ttm)
2.96%
Return on Equity (ttm)
8.22%
Revenue (ttm)
3.15B
Net Income Avi to Common (ttm)
304.7M
Diluted EPS (ttm)
1.68
Balance Sheet and Cash Flow
Total Cash (mrq)
1.18B
Total Debt/Equity (mrq)
53.65%
Levered Free Cash Flow (ttm)
232.08M